BioCentury | Feb 23, 2021
Distillery Therapeutics

Endocytic protein SH3GL1 as an autoimmune arthritis target

DISEASE CATEGORY: Autoimmune INDICATION: Arthritis; rheumatoid arthritis (RA) Inhibiting the endocytic protein SH3GL1 could treat autoimmune arthritis, including RA. CD4+ T cells from eight RA patients had higher mRNA levels of SH3GL1 than cells from...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...drug Lutathera. A year later, Novartis acquired Endocyte Inc....
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

...for about $8.7 billion, the 2017 and 2018 acquisitions of Advanced Accelerator Applications S.A. and Endocyte Inc....
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...in 2017, gaining the lutetium 177-based neuroendocrine tumor drug Lutathera. A year later, Novartis acquired Endocyte Inc....
...radiotherapy in Phase III testing for PSMA-positive metastatic CRPC due to read out in 2020. Endocyte...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BioCentury | Dec 21, 2019
Product Development

China a priority for Novartis’ Narasimhan

...his tenure began, Novartis has engaged in a variety of deal styles. It has acquired Endocyte Inc....
...Medicines Co., they’re right in our core therapeutic areas where we have existing presence, or Endocyte...
BioCentury | Dec 9, 2019
Company News

Novartis downsizing internal efforts on CAR T in solid tumors

...Novartis has added radioligands via two separate acquisitions: Advanced Accelerator Applications S.A. in 2018 and Endocyte Inc....
...later that same year. Novartis paid $3.9 billion for Advanced Accelerator and $2.1 billion for Endocyte...
BioCentury | Nov 26, 2019
Company News

After mid-decade makeover, Medicines Co. accepts Novartis' $9.7B bid on eve of inclisiran submission

...acquired gene therapy company AveXis Inc. and radio-ligand therapy companies Advanced Accelerator Applications S.A. and Endocyte Inc....
...largest at $8.7 billion; Novartis paid $3.9 billion for Advanced Accelerator and $2.1 billion for Endocyte...
BioCentury | Aug 13, 2019
Company News

Management tracks: Chouraqui leaving Novartis; plus iTeos, Immunovant, Biodesix

...Belgium) hired Matthew Call as COO, with additional business development responsibilities. Call was COO of Endocyte Inc....
Items per page:
1 - 10 of 199
BioCentury | Feb 23, 2021
Distillery Therapeutics

Endocytic protein SH3GL1 as an autoimmune arthritis target

DISEASE CATEGORY: Autoimmune INDICATION: Arthritis; rheumatoid arthritis (RA) Inhibiting the endocytic protein SH3GL1 could treat autoimmune arthritis, including RA. CD4+ T cells from eight RA patients had higher mRNA levels of SH3GL1 than cells from...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...drug Lutathera. A year later, Novartis acquired Endocyte Inc....
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

...for about $8.7 billion, the 2017 and 2018 acquisitions of Advanced Accelerator Applications S.A. and Endocyte Inc....
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...in 2017, gaining the lutetium 177-based neuroendocrine tumor drug Lutathera. A year later, Novartis acquired Endocyte Inc....
...radiotherapy in Phase III testing for PSMA-positive metastatic CRPC due to read out in 2020. Endocyte...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BioCentury | Dec 21, 2019
Product Development

China a priority for Novartis’ Narasimhan

...his tenure began, Novartis has engaged in a variety of deal styles. It has acquired Endocyte Inc....
...Medicines Co., they’re right in our core therapeutic areas where we have existing presence, or Endocyte...
BioCentury | Dec 9, 2019
Company News

Novartis downsizing internal efforts on CAR T in solid tumors

...Novartis has added radioligands via two separate acquisitions: Advanced Accelerator Applications S.A. in 2018 and Endocyte Inc....
...later that same year. Novartis paid $3.9 billion for Advanced Accelerator and $2.1 billion for Endocyte...
BioCentury | Nov 26, 2019
Company News

After mid-decade makeover, Medicines Co. accepts Novartis' $9.7B bid on eve of inclisiran submission

...acquired gene therapy company AveXis Inc. and radio-ligand therapy companies Advanced Accelerator Applications S.A. and Endocyte Inc....
...largest at $8.7 billion; Novartis paid $3.9 billion for Advanced Accelerator and $2.1 billion for Endocyte...
BioCentury | Aug 13, 2019
Company News

Management tracks: Chouraqui leaving Novartis; plus iTeos, Immunovant, Biodesix

...Belgium) hired Matthew Call as COO, with additional business development responsibilities. Call was COO of Endocyte Inc....
Items per page:
1 - 10 of 199